文献速递骨质疏松与代谢性骨病

甲状腺功能亢进患者地舒单抗诱发低钙血症一例

Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report.
PubMed 文献 · Osteoporos Int · 2021-07-07

本文报告一例48岁绝经后女性,患甲状腺功能亢进和骨质疏松,接受丙硫氧嘧啶200 mg/日及地舒单抗治疗2个月后出现手足麻木刺痛,诊断为低钙血症(钙5.8 mg/dL;离子钙0.83 mmol/L),经阿法骨化醇0.5 μg/日与碳酸钙3000 mg/日治疗后症状改善、血钙正常。提示高骨转换疾病如甲亢可能增加地舒单抗相关低钙血症风险,需谨慎。

要点

  • 甲亢等高骨转换状态可能增加地舒单抗诱发低钙血症的风险。
  • 地舒单抗治疗前应评估并纠正低钙血症风险因素。
  • 出现手足麻木刺痛需警惕低钙血症并监测血钙。

核心结论

  • 甲状腺功能亢进等高骨转换疾病患者使用地舒单抗时,低钙血症风险可能增加,需谨慎。

研究设计与样本

  • 个案报告:一例48岁绝经后女性,患甲状腺功能亢进和骨质疏松。

主要发现

  • 患者接受丙硫氧嘧啶200 mg/日及地舒单抗治疗2个月后出现手足麻木刺痛,诊断为低钙血症(钙5.8 mg/dL;离子钙0.83 mmol/L)。
  • 给予阿法骨化醇0.5 μg/日与碳酸钙3000 mg/日治疗后症状改善,血清钙水平恢复正常。

临床怎么用

  • 对甲亢等高骨转换状态患者使用地舒单抗前应评估低钙血症风险并监测血钙。
  • 出现手足麻木刺痛等症状时应考虑低钙血症并及时处理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Denosumab is a humanized monoclonal antibody targeting the receptor activator of nuclear factor kappa-B ligand (RANKL). Denosumab is an effective treatment for osteoporosis but can cause hypocalcemia. We present a case of denosumab-induced hypocalcemia in a patient with hyperthyroidism with a high bone turnover state. A 48-year-old postmenopausal woman was diagnosed with hyperthyroidism and osteoporosis and received antithyroid drugs (propylthiouracil 200 mg/day) and denosumab. After 2 months of taking medication, the patient complained of numbness and tingling in the hands and feet and was diagnosed with hypocalcemia (calcium, 5.8 mg/dL; ionized calcium, 0.83 mmol/L). Alfacalcidol (0.5 μg/day) and calcium carbonate (3000 mg/day) were prescribed. Subsequently, the patient's symptoms improved, and her serum calcium level normalized. The risk of denosumab-induced hypocalcemia may be increased in patients with diseases related to high bone turnover, such as hyperthyroidism; therefore, caution is needed.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Park SY, Kim J, Chung HY, et al. Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report. Osteoporos Int. 2021. PMID: 34232341. doi:10.1007/s00198-021-06059-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。